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One of the major barriers to HIV-1 eradication is the presence of the latent 
reservoir, which is established very early in infection. This reservoir is widely dispersed 
throughout lymphoid tissue in the body. Resting latently infected CD4+ T cells are the 
best established cell type in the reservoir, and a number of clinical trials are currently 
investigating the effects of latency reversal agents on these cells. In order to determine 
the efficacy of such compounds, assays that measure the frequency of latently infected 
cells are of extreme importance. The gold standard quantitative viral outgrowth assay 
(QVOA) relies on mitogen phytohemagglutinin (PHA) in the presence of irradiated 
allogeneic PBMC (feeders) to achieve a global state of resting CD4+ T cell activation, 
followed by addition of PHA-stimulated CD4+ lymphoblasts at two time points for viral 
expansion. The need for addition of feeders followed by a step to remove PHA makes 
this assay costly and labor intensive. To address this issue, we developed an assay that 
does not require feeders and is less labor intensive. This new assay utilizes anti-CD3 and 
anti-CD28-coated microbeads for a more physiological activation of T cells. A side-by-
side comparison of this assay to the conventional QVOA suggests that the sensitivity of 
the two techniques is similar. Additionally, stimulation with anti-CD3/CD28 coated 
microbeads resulted in faster activation of resting CD4+ T cells as determined from the 
percentage of cells expressing appropriate activation markers. The results indicate that 
this new assay could represent a sensitive, less expensive approach to quantifying the 
frequency of latently infected cells, which would have major implications for the HIV-1 
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CHAPTER 1 - INTRODUCTION 
 
Historical Perspective 
The June 5, 1981 edition of the Morbidity and Mortality Weekly Report 
(MMWR) from the Center for Disease Control and Prevention (CDC) deserves a special 
place in the history of immunology. One of the cases in the Epidemiologic Notes and 
Reports section covered a period spanning late fall of 1980 and early spring of 1981, 
whereas three different hospitals in the Greater Los Angeles Area treated five new cases 
of young men, all self-identified as homosexuals, for biopsy-confirmed Pneumocystis 
carinii. The latter is a rather rare condition in the United States and is primarily 
associated with severe immunosuppression. The condition of two of the patients 
deteriorated quickly and both eventually died a month after being hospitalized despite 
being put on standard treatment. The patients had no prior contacts with each other and 
three of them had significantly decreased white blood cell counts. “All of the above 
observations suggest the possibility of a cellular-immune dysfunction related to a 
common exposure that predisposes individuals to opportunistic infections such as 
pneumocystosis…” (Disease Control (CDC), 1981). This report was later recognized as 
the first report of the acquired immune deficiency syndrome (AIDS) in the United States 
(Disease Control & (CDC), 2001). 
After subsequent epidemiologic observations suggested that AIDS was linked to 
an infectious pathogen and transmitted through sexual intercourse as well as 
contaminated blood, numerous research groups around the world embarked on a search 
of the primary etiologic agent of the disease. It was not until 1983 that Francoise Barre-
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Sinoussi and Luc Montaigner from the Institute Pasteur in Paris were able to isolate the 
etiologic agent, a T-lymphotropic retrovirus, from the lymph node of a person with 
generalized lymphadenopathy of an unknown origin (Barré-Sinoussi et al., 1983). This 
finding was confirmed a year later by Robert Gallo, who demonstrated the connection 
between the infection and virus-specific immune responses in patients in addition to 
among the people at risk (Gallo et al., 1984; Popovic, Sarngadharan, Read, & Gallo, 
1984; Sarngadharan, Popovic, Bruch, Schupbach, & Gallo, 1984). Two years later, in 
1986, at around the same time that the latter AIDS-associated retrovirus was given a 
name of human immunodeficiency virus (HIV-1, (Coffin et al., 1986)), a related, but 
immunologically distinct virus was discovered in West Africa and termed HIV-2 (Clavel 
et al., 1986). While HIV-2 remained largely confined to its geographic area of origin, 
namely West Africa, HIV-1 has become a pandemic affecting millions of people around 
the world (Nyamweya et al., 2013). 
 
HIV Epidemiology 
According to the most recent statistics from the World Health Organization 
(WHO) and the CDC, there are currently 37 million people infected with HIV-1 
worldwide and more than a million in the United State alone (“CDC - Statistics Overview 
- Statistics Center - HIV/AIDS”, “WHO | HIV/AIDS”). Every day there are 5,600 new 
infections in the world (“amfAR :: Statistics: Worldwide :: The Foundation for AIDS 
Research :: HIV / AIDS Research”). Sub-Saharan Africa, the region hit the hardest by the 
HIV/AIDS pandemic, has nearly 25 million people living with the infection alone, which 
is approximately two-thirds of all HIV-1 infected people (“Overview: HIV/AIDS - WHO 
3 
| Regional Office for Africa”). In the past decade, the overall trends in the global 
epidemiology of HIV have seen a dramatic change due to the increased number of people 
from low- and middle-income countries having access to the antiretroviral therapy 
(“WHO | Global update on HIV treatment 2013: Results, impact and opportunities,”). In 
fact, as a result of people living longer due to the success of the combined antiretroviral 
therapy (cART), the global prevalence of HIV has increased over the years, while the 
incidence has decreased (“Fact sheet 2015 | UNAIDS,”). However, despite the success in 
the global fight against HIV/AIDS, the latter is still a major contributor to the global 
burden of disease. In 2010 alone, HIV was found to be the leading cause of disability-
adjusted life years for people aged 30-44 years worldwide, in addition to being the fifth 
leading cause for all ages (Ortblad, Lozano, & Murray, 2013).   
 
HIV-1 Infection and Pathogenesis 
 HIV-1 is a lentivirus belonging to the family Retroviridae in the subfamily of 
Orthoretrovirinae (Fanales-Belasio, Raimondo, Suligoi, & Buttò, 2010). The virion itself 
consists of a genome, which is made of 2 single strands of positive-sense RNA 
containing 9 genes encoding 15 proteins (Figure 1) (Frankel & Young, 1998). The 
internal viral RNA is first protected by capsid proteins, and further covered with the 
remaining critical enzymes including reverse transcriptase, integrase, and protease by an 
outer membrane. The latter has as part of its structural architecture envelope 
glycoproteins, gp120/gp41 that facilitates binding and infection of the target cells through 
the interaction with the CD4 receptor and chemokine co-receptors.  
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CD4+ T cells and macrophages, which are the primary coordinators of the 
adaptive and innate immune systems, are the major targets for HIV. The transmission of 
the virus occurs predominantly through a sexual contact, and less common through other 
modes of exposure such as mechanical (needlesticks), breastfeeding, or blood 
transfusions. In the event of a sexual transmission, the virus or infected cells first 
penetrate the epithelium and find their way to the lamina propria where mucosal CD4+ T 
cells and macrophages are exposed to the virus via interactions with the dendritic cells 
(Pantaleo & Fauci, 1996). Afterward, the infected cells migrate to local lymph nodes 
where the virus is spread to local cells, ultimately resulting in the widespread systemic 
infection. As noted earlier, CD4+ T cells and macrophages are the primary targets for 
infections. This is explained by their expression of major receptors and co-receptors 
required for effective infection and dissemination of the virus, namely CD4 and CCR5 or 
CXCR4.  
HIV replication inside the target cell generally involves reverse transcription of 
RNA to DNA followed by the nuclear transport and integration of viral DNA in the host 
genome. If successful, the proviral DNA will then undergo transcription into mRNA 
followed by translation, and assembly and release of infectious virions (Figure 2). 
Following the initial peak in viremia, HIV-specific humoral and cell-mediated responses 
can be detected by various methods. Anti-HIV antibodies as well as cytotoxic T 
lymphocytes (CTLs) are detected early in the infection and are responsible for the initial 
drop in viremia (Figure 3). A majority of the patients who are not receiving any 
medication usually die within ten years after acquiring the infection, most commonly due 
to opportunistic infections associated with the development of the immunodeficiency 
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(Deeks & Walker, 2007). Moreover, at about the same time as the epidemic took off, 
reports started appearing in the literature about individuals who were capable of 
sustaining a durable control over the virus. These individuals were positive by regular 
HIV antibody tests; however, they lacked any detectable virus, meaning their viral loads 
were consistently below 50 RNA copies HIV1 per milliliter of blood. They are now 
commonly referred to as elite controllers, or long-term non-progressors, constituting less 
than 1% of the HIV-infected population (O’Connell, Bailey, & Blankson, 2009; Okulicz 
& Lambotte, 2011). Interestingly enough, despite the lack detectable viremia, such 
individuals have been reported to be at a higher risk of developing atherosclerosis when 
compared to HIV-negative patients, suggesting factors other than cART are responsible 
for elevated risk of cardiovascular risk in HIV-infected individuals (Gandhi, Sax, & 
Grinspoon, 2012). Moreover, even among individuals capable of controlling the 
infection, a number of studies found a loss of control over time (Okulicz et al., 2009) 
further showing the importance of finding a cure. 
 
The Challenge 
The advent of combination antiretroviral therapy (cART) in the mid-90s has 
dramatically increased the longevity while simultaneously reducing the mortality and 
morbidity commonly associated with HIV-1 infections. In adherent patients, treatment 
with cART has been shown to reduce plasma viral load to below the limit of detection in 
clinical setting (50 copies HIV-1 RNA/mL of blood) (Sedaghat et al., 2009). However, 
despite all the advantages of this regiment, current treatment is not curative. Numerous 
studies have shown that patients on prolonged cART still harbor HIV-1 in its latent form, 
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fully replication-competent and integrated into the genomes of a small percentage of 
resting memory CD4+ T cells, which now serves as the best characterize cell reservoir for 
the HIV-1 in its latent form (Eisele & Siliciano, 2012). These cells are largely non-
permissive of HIV-1 gene expression (Ruelas & Greene, 2013) and are of the long-lived 
lineage, as dictated by the biology of memory T cells, with a half-life of approximately 
44 months (Blankson et al., 2000; Siliciano et al., 2003). Once the treatment is 
interrupted, internal signals allow for the viral genes to get reactivated and start the 
production of the infectious particles once again, requiring reinitiating the therapy 
(Harrigana, Whaley, & Montaner, 1999). It should also be noted that more often than not, 
the latent reservoir is composed of defective (i.e. replication-incompetent viruses) which 
arise due to error-prone enzyme reverse transcriptase. Such proviruses can occasionally 
revert to replication-competent variants, however it has been shown to be a relatively rare 
event (Ho et al., 2013; Sanchez, Xu, Chermann, & Hirsch, 1997; Simon-Loriere & 
Holmes, 2011). All in all, the profound stability of this HIV-1 reservoir prevents 
eradication with cART and is considered a major obstacle in fighting the pandemic 
(Deeks et al., 2012; Durand, Blankson, & Siliciano, 2012).  
Currently, the most commonly circulated approach to eliminate the latent 
reservoir is to reverse latency via pharmacological methods so that infected cells can be 
eliminated either via cytopathic events or through the action of HIV-1 specific cytolytic T 
lymphocytes. This approach is also known as “shock-and-kill” (Nancie M Archin & 
Margolis, 2014; Deeks, 2012; Margolis, 2014). A number of clinical trials are currently 
investigating the effects of latency reversal agents on resting CD4+ T cells (Nancy M 
Archin et al., 2014; Rasmussen et al., 2014; Wei et al., 2014). In order to determine the 
7 
efficacy of such compounds, assays that measure the frequency of latently infected cells 
are of extreme importance (Bruner, Hosmane, & Siliciano, 2015). These assays work 
through the induction of global activation of CD4+ T cells in vitro in order to stimulate 
replication of latent virus.  Methods used to achieve global activation include stimulation 
of resting CD4+ T cells with phytohemagglutinin (PHA) and irradiated allogeneic feeders 
(Finzi et al., 1997; Siliciano & Siliciano, 2005) or with immobilized anti-CD3 and anti-
CD28 antibodies (Wong et al., 1997) or a bispecific CD3/CD8 antibody that 
simultaneously activates CD4+ T cells and depletes CD8+ T cells (Tremblay et al., 2000).   
Currently, the PHA/feeders quantitative viral outgrowth assay (QVOA) is 
considered the gold standard for measuring the size of the latent reservoir (Siliciano & 
Siliciano, 2005). The assay induces activation of resting CD4+ T cells by the addition of 
PHA in the presence of a tenfold excess of irradiated allogeneic peripheral blood 
mononuclear cells (PBMCs).  After overnight stimulation, the media containing PHA is 
removed and replaced with fresh media before CD4+ lymphoblasts are added to 
propagate the virus. The need for the addition of feeders followed by a PHA removal step 
makes this assay costly and labor intensive. The development of alternative assays which 
are less costly and labor intensive is a major priority for the HIV-1 cure agenda (Deeks et 
al., 2012). 
The sensitivity of the PHA/feeders assay has not been directly compared to that of 
any of the antibody-based assays to the best of our knowledge. The antibody-based 
assays do not require the addition of feeders and therefore are less labor intensive. The 
first antibody-based assays used either immobilized anti-CD3 and anti-CD28 antibodies 
(Wong et al., 1997) or a soluble CD3/CD8 bispecific antibody. The two assays were 
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shown to have roughly the same sensitivity in a head to head comparison (Tremblay et 
al., 2000). A recent study has shown that anti-CD3/CD28-coated magnetic beads are 
more effective at stimulating primary CD4+ T cell growth than soluble anti-CD3 
antibodies (Li & Kurlander, 2010). As such, we hypothesized that the more potent global 
stimulation and expansion of resting CD4+ T cells induced by anti-CD3/CD28-coated 
microbeads would lead to better outgrowth of latent virus. We developed a viral 
outgrowth assay with these beads and performed a direct comparison of the sensitivity of 
this new assay to that of the standard PHA/feeders assay.   
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Figure 1. Representation of the HIV-1 virion 
A mature HIV-1 virion is composed of two copies of positive double-stranded RNA in 
addition to several proteins and enzymes that are essential for the infection and 
replication of the virus in the target cell.  
(© Thomas Splettstoesser/Wikimedia Commons/ license CC-BY-SA-4.0) 
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Figure 2. HIV-1 Replication 
Schematic overview of the infection of an activated CD4+ T lymphocyte or macrophage 
by HIV. (A) Fusion and entry. (B) Reverse transcription. (C) Nuclear import and viral 
integration. (D) Proviral transcription and mRNA export. (E) Viral RNA translation and 
polyprotein assembly. (F) Viral assembly and release 




Figure 3. Natural History of HIV Infection in Untreated Individual 
The first several weeks are characterized by acute flu-like symptoms with high viral titers 
in the blood. A restoration in CD4+ T cell count is observed after the activation of the 
adaptive immune system. Clinical latency, a largely asymptomatic phase, follows. 
Opportunistic infections develop as the CD4+ T cell count falls (symptomatic phase). The 
patient is said to have AIDS when the CD4+ T cell count falls below 200 cell/ul 




CHAPTER 2 - METHODOLOGY 
 
Patient Cohort 
A total of thirteen HIV-1 infected individuals were enrolled in this study. Among 
them, three patients were elite suppressors with undetectable viral load. The remaining 
ten HIV-1 infected patients were on suppressive cART for more than a year when 
enrolled in this study. The clinical characteristics of these patients are presented in Table 
1.  The study was approved by the Johns Hopkins Institutional Review Board. All 
patients and HIV-1 negative donors provided written consent before participating in this 
study. 
 
Isolation of Resting CD4+ T Cells 
 Peripheral blood was obtained from HIV-1-infected patients in a 30 ml syringe 
preloaded with 4 ml of acid-citrate-dextrose solution [ACD, Sigma-Aldrich, C3821] as an 
anticoagulant or a 60 ml syringe with 8 ml of ACD. We also collected blood from healthy 
donors. The latter was performed by using a 60 ml syringe with 700 ul of heparin 
(Appendix – Materials 2) as an anticoagulant. PBMCs were subsequently isolated by 
Ficoll gradient centrifugation (Appendix - Methods 2). CD4+ T cells were isolated from 
bulk PBMCs by negative selection (Appendix – Methods 3). Afterward, we performed 
isolation of resting CD4+ T lymphocytes (Appendix – Methods 4). Purified resting CD4+ 




Viral Outgrowth Assays 
Resting CD4+ T cells from each patient were divided into 2 aliquots – 1 aliquot 
was used for the CD3/CD28 assay, the other for the PHA/feeders QVOA. We initially 
started with 25 to 30 replicates of 2x105 resting CD4+ T cells.  For the PHA/feeders 
assay, 2x105 cells were cultured with 2.5 million irradiated PBMCs (Appendix – Methods 
5) in each well of a 24-well plate in 2ml of STCM (Appendix – Materials 4). 
For the alternate assay, 2x105 cells were cultured in each well of a 96-well plate in 
200 ul of STCM described above and 5 ul of anti-CD3/CD28-coated microbeads 
(ThermoFisher Scientific, 11161D). 
CD4+ T cells were stimulated for 18 hours in both assays. Afterward, for the 
PHA/feeders assay, the PHA was washed off and 0.5 to 1x106 lymphoblasts were added 
to each well (Appendix – Methods 6 and 7). For the alternate assay, the cells and beads 
were resuspended and transferred to 48-well plate wells with 0.5 to 1 million 
lymphoblasts (Appendix – Methods 7) per well. 
A new round of 0.5 to 1 million lymphoblasts were added to each well on day 9 
for both assays.  
In patients where virus was not obtained using multiple replicates of 2x105 CD4+ 
T cells, the assay was repeated with 20 to 30 replicates of 1x106 resting CD4+ T cells. 
For the PHA/feeders assay, 1x106 cells were cultured with 10 million irradiated 
feeders in each well of a 6-well plate in 8ml of STCM. 
For the anti-CD3/CD28 beads-based assay, 1x106 cells were cultured in each well 
of a 48-well plate in 1ml of STCM and 25 ul of anti-CD3/CD28-coated microbeads. 
14 
CD4+ T cells were stimulated for 18 hours in both assays. For the PHA/feeders 
assay, the PHA was removed and 2 to 4 million lymphoblasts were added to each well. 
For the alternate assay, the cells and beads were resuspended and transferred to 
12-well plate wells with 2 to 4 million lymphoblasts added per well. 
A new round of 2 to 4 million blasts were added to each well on day 9 for both 
assays. 
In patients where virus was not obtained using replicates of 1x106 CD4+ T cells, 
the anti-CD3/CD28 microbead assay was repeated with 30 to 45 replicated of 2x105 cells 
with the addition of a spinoculation step during the first round of lymphoblast addition. In 
brief, 2x105 blasts in 20 ul STCM was added to each well of a 96-well plate. It was then 
spinoculated at 1200 x G for 2 hours at 37°C. Cells from each well were then transferred 
to a 48 well plate and 8x105 additional blasts were added to each well. The volume was 
adjusted to 1 ml with the addition of 700 ul of STCM. 
Lymphoblasts from the same healthy donors were always used to amplify virus 
from the two assays for each patient in order to minimize the number of variables in the 
comparison 
Supernatants from each well were tested for HIV-1 p24 protein by ELISA 
(Appendix – Methods 9) on day 12 and repeated on day 19 for the negative wells. For 
both the anti-CD3/CD28 bead-based assay and the standard PHA/feeders assay, 
incubation was done at 37°C under 5% CO2. 




Flow Cytometric Analysis of Activated Resting CD4+ T Cells 
To compare the activation levels achieved in the 2 donors, CD4+ T cells were 
obtained from three HLA-A2-positive healthy donors. 2x105 cells were plated in 
triplicates for each time point and stimulated as described above for the anti-CD3/CD28 
and PHA/feeders assays. The feeders were obtained from a HLA-A2-negative HIV-
uninfected donor so that we could easily distinguish between the feeders and the purified 
resting CD4+ T cells using an antibody specific for HLA-A2. After 18 hours of 
incubation, the cells from the standard assay were stained with CD3-PacBlue (BD), CD8-
APC-H7 (BD), CD4-PE (BD), HLA-A2-PerCP-Cy5.5 (BioLegend), CD25-FITC (BD), 
HLA-DR-APC (BD), and CD69-BV605 (BD). For the CD3/CD28 assay, the beads were 
removed prior to staining. Cells were fixed and permeabilized with Cytoperm/Cytofix Kit 
(BD). Stained cells were analyzed by flow cytometry on a FACSCanto II (BD). The 
procedure was repeated on day 2 and 3 (Appendix – Methods 10, 11). 
 
Data Analysis 
Flow cytometry data was analyzed using FlowJo v10.0.7. All statistical analysis 
was performed in GraphPad Prism v6.01. A Wilcoxon matched-pairs signed rank test was 
used for statistical analysis. Frequencies of infected cells (infectious units per million 
wells [IUPM]) were based on the percentage of positive replicates and were calculated as 
previously described (Siliciano & Siliciano, 2005).  
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Table 1. Clinical characteristics of the patients studied 
Subject Current CD4+ 
T cell count 
Nadir CD4+ 





PT 8 424 18 8 years 3TC, RAL EFV 
PT 10 1109 NA 12 years 3TC, ABC, DTG 
PT 11 1032 177 8 years TDF, FTC, DRV/r 
PT 12 860 494 3 years 3TC, RAL EFV 
PT 14 646 12 4 years DRV/r, DTG 
PT 16 921 203 5 years 3TC, ABC, DTG 
PT 21 541 388 3 years FTC, TDF, RPV 
PT 40 705 NA 4 years FTC, TDF, EFV 
PT 42 1140 NA 4 years MVC, DRV/r,RAL 
PT 45 402 19 7 years DTG, DRV/r 
ES 31 NA NA NA NA 
ES 23 NA NA NA NA 
ES 46 NA NA NA NA 
 
3TC: lamivudine, ABC: abacavir, FTC: emtricitabine, TDF: tenofovir, DTG: 
dolutegravir, EFV: efavirenz, RPV: rilpivarine, RAL: raltegravir, MVC: maraviroc, 
DRV/c: cobicistat boosted darunavir, DRV/r: ritonavir boosted darunavir 
NA: Not available  
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Figure 4. The standard PHA/feeders and anti-CD3/CD28 viral outgrowth assays 
Schematic representation of the side-by-side experimental setup using PHA and -
irradiated allogeneic PBMCs for the PHA/feeders standard and anti-CD3/CD28 







CHAPTER 3 - RESULTS 
  
Stimulation with anti-CD3/CD28-coated microbeads results in faster activation of 
resting CD4+ T cells 
 We first compared the level of immune activation achieved with the traditional 
PHA/feeders assay to that achieved with anti-CD3/CD28-coated microbeads using 
resting CD4+ T cells from 3 healthy donors. Analysis of T cell activation by flow 
cytometry showed that stimulation with microbeads results in faster activation of resting 
CD4+ T cells as determined from the percentage of cells expressing very early (CD69), 
early (CD25), and late (HLA-DR) activation markers (Figure 5) (Reddy, Eirikis, Davis, 
Davis, & Prabhakar, 2004). Notably, on day 1 post stimulation, between 80-100% of cells 
stimulated with anti-CD3/CD28 beads expressed CD69 and CD25, while for the 
PHA/feeders activated cells the values ranged from 15-50%. Figure 6 shows the overall 
gating strategy. 
 
The sensitivity of the anti-CD3/CD28 bead-based assay is similar to that of the 
PHA/feeders assay 
We originally plated 25 to 30 replicates of 2x105 resting CD4+ T cells per well for 
both assays. The median percentage of positive wells was 15% (range from 0% to 40%) 
for the standard PHA/feeders assay and 10% (range from 0% to 68%) for the bead-based 
assay. No virus was isolated from the PHA/feeders assay in 1 of 10 patients tested (PT40) 
whereas no virus was obtained with the bead-based assay in 4 out of 10 patients (PT8, 
PT14, PT21, and PT40) (Figure 7A).  
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To improve the sensitivity of both assays, we repeated the experiment with more 
patient cells using 20 to 30 replicates of 1x106 resting CD4+ T cells from the four patients 
from whom no virus was obtained in one or both assays (PT8, PT14, PT21, and PT40). 
While virus was amplified in all 4 patients with the PHA/feeders assay, no virus was 
amplified from PT21 and PT40 with the bead-based assay (Figure 7B). The median 
percentage of positive wells was 19% (range from 13% to 40%) for the PHA/feeders 
assay and 5% (range from 0% to 10%) for the bead-based assay. IUPMs were calculated 
using the 2x105 cell replicates for the 6 patients for whom virus was amplified with both 
assays. The 1x106 cell replicates were used to determine the IUPMs for the other 4 
patients. No significant difference was observed between the frequency of latently 
infected resting CD4+ T cells as measured by the PHA/feeders assay compared to the 
bead-based assay (Figure 7C, Wilcoxon matched-pairs signed rank test, p = 0.5469).  
Moreover, there was a significant correlation between the frequency of latently infected 
cells measured in the two different assays (Figure 7D, Pearson’s correlation coefficient, r 
= 0.8520, p = 0.0017). Raw data for the p24 assays is provided in Table 2 through Table 
15. We were not able to detect any virus following the spinoculation procedure (data 
shown in Table 16 through Table 18). Moreover, the anti-CD3/CD28 assay was not able 
to detect virus from the elite controllers, while the PHA/feeders detected virus in one of 





Figure 5. Stimulation of lymphocytes with anti-CD3/CD28 microbeads exhibits 
faster activation of resting CD4+ T cells as compared to the PHA/feeders standard 
viral outgrowth assay 
Resting CD4+ T cells from three healthy donors were activated with standard 
PHA/feeders or with anti-CD3/CD28 microbeads and analyzed for the expression of 
markers of cellular activation by flow cytometry. (A) CD69 Expression. (B) CD25 
Expression. (C) HLA-DR Expression. 
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Figure 6. Representative FACS gating strategy for cell populations expressing 
different activation markers 
Initial lymphocyte populations gated based on forward and side scatter properties. HLA-





Figure 7. The standard PHA/feeders and anti-CD3/CD28-beads-based viral 
outgrowth assays yield comparable results 
(A) For both assays, 2x105 cells were plated side-by-side in appropriate multi-well 
culture plates. The percentage of wells positive for the p24 antigen is shown. N is the 
number of wells tested for each assay. (B) For both assays, 1x106 cells were plated side-
by-side in appropriate multi-well culture plates. The percentage of wells positive for the 
p24 antigen is shown. N is the number of wells tested for each assay. (C) Statistical 
comparison of the infectious units per million cells (IUPM) values using the 2 assays by 
Wilcoxon matched-pairs signed rank test.  Virus was not detected in 2 patients with the 
anti-CD3/CD28 bead-based assay (PT21 and PT40) and the upper limit of the IUPM for 
both patients is shown in open red circles. (D) The correlation of infectious units per 
million cells (IUPM) values using the standard PHA/feeders and anti-CD3/CD28 assays 
(Pearson’s correlation coefficient, r). PT21 and PT40 are shown as open circle. PT42 and 
PT10 are shown as a square.  
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Table 2. Setup of the p24 ELISA Assay for PT8 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well. 
G – controls. 
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Table 3. Setup of the p24 ELISA Assay for PT10 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well. Red 
highlight – well is not applicable for further analysis. G – controls.  
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Table 4. Setup of the p24 ELISA Assay for PT11 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well. 
G – controls. 
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Table 5. Setup of the p24 ELISA Assay for PT12 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well. 
G – controls. 
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Table 6. Setup of the p24 ELISA Assay for PT14 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well. 
G – controls. 
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Table 7. Setup of the p24 ELISA Assay for PT16 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well. Red 
highlight – well is not applicable for further analysis. G – controls. 
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Table 8. Setup of the p24 ELISA Assay for PT21 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well. Red 
highlight – well is not applicable for further analysis. G – controls. 
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Table 9. Setup of the p24 ELISA Assay for PT40 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. G – controls. 
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Table 10. Setup of the p24 ELISA Assay for PT42 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well.  
G – controls. 
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Table 11. Setup of the p24 ELISA Assay for PT45 (2x105 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight denotes a positive well. 
G – controls. 
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Table 12. Setup of the p24 ELISA Assay for PT8 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well. Red 
highlight – well is not applicable for further analysis. G – controls. 
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Table 13. Setup of the p24 ELISA Assay for PT14 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well.  
G – controls. 
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Table 14. Setup of the p24 ELISA Assay for PT21 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well.  
G – controls.  
37 
Table 15. Setup of the p24 ELISA Assay for PT40 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well.  
G – controls. 
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Table 16. Setup of the p24 ELISA Assay for PT40 (2x105 cells/well) with 
spinoculation step and raw data 
The overall setup for the p24 ELISA with raw data output. N – anti-CD3/CD28-beads-
based assay. NS – anti-CD3/CD28-beads-based assay with spinoculation step.  
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Table 17. Setup of the p24 ELISA Assay for PT21 (2x105 cells/well) with 
spinoculation step and raw data, well 1 through 30 
The overall setup for the p24 ELISA with raw data output. N – anti-CD3/CD28-beads-
based assay. NS – anti-CD3/CD28-beads-based assay with spinoculation step. 
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Table 18. Setup of the p24 ELISA Assay for PT21 (2x105 cells/well) with 
spinoculation step and raw data, well 31 through 45 
The overall setup for the p24 ELISA with raw data output. N – anti-CD3/CD28-beads-
based assay. NS – anti-CD3/CD28-beads-based assay with spinoculation step. 
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Table 19. Setup of the p24 ELISA Assay for ES31 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. G – controls. 
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Table 20. Setup of the p24 ELISA Assay for ES23 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. G – controls. 
  
43 
Table 21. Setup of the p24 ELISA Assay for ES46 (1x106 cells/well) and raw data 
The overall setup for the p24 ELISA with raw data output. C – standard PHA/feeders 
assay. N – anti-CD3/CD28-beads-based assay. Yellow highlight - positive well.  
G – controls. 
  
44 
CHAPTER 4 – DISCUSSION AND FUTURE DIRECTIONS 
 
We demonstrated that the anti-CD3/CD28-bead-based assay is capable of 
quantifying the HIV-1 latent reservoir in resting CD4+ T cells with a similar sensitivity 
compared to that achieved by the conventional PHA/feeders QVOA. While the former 
induces a more rapid stimulation of target cells than the PHA/feeders assay, the latter was 
more efficient at amplifying virus when replicates of 2x105 were tested. Of note, the 3 
patients from whom virus was selectively not amplified with the bead-based assay had 
relatively low frequencies of latently infected cell sin the PHA/feeders assay. Just 1 out 
of 25 wells was positive for PT14 and PT21 and 3 out of 30 wells were positive for PT8. 
When higher numbers of cells were tested, virus was amplified from all 4 patients using 
the PHA/feeders assay and 2 patients with the bead-based assay. Again, the percentage of 
positive wells in PHA/feeders assay in these 2 patients (PT21 and PT40) was relatively 
low (4 out of 30 wells). Thus, while there was not a significant different in the sensitivity 
between the 2 assays, the PHA/feeders QVOA appeared to be slightly more effective at 
viral amplification in some patients. Interestingly enough, one of these patients was a 
long-term non-progressor, which could explain the inability of the anti-CD3/CD28 assay 
to detect virus. As shown in the Table through Table 21, the microbeads-based assay was 
not able to detect any amount of virus either. However, given the fact that the second 
patient in the anti-CD3/CD28 spinoculation attempt was not a controller, there seems to 
be a different explanation for the lack of viral amplification. First, it is possible that 
stimulation with microbeads does not achieve a similar level of global T cell activation 
compared to the PHA. Secondly, the addition of allogeneic feeders serves as a secondary 
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stimulus for activation, possibly due to the presence of macrophages and dendritic cells. 
However, data in Figure 5 seems to show faster activation in response to the ant-
CD3/CD28 beads and no the PHA. 
The advantage of the PHA/feeders assay in being more effective at viral 
amplification in some patients must be balanced against the fact that the need for feeders 
and a PHA washout step makes it more labor intensive and costly than the bead-based 
assay. An additional measure for simplifying the bead-based assay would be to use a cell 
line such as MOLT-4/CCR5 instead of lymphoblasts from healthy donors for amplifying 
virus as previously described for the PHA/feeders assay (Laird et al., 2013). The bead-
based assay would also be easier to use for the repeated stimulation of CD4+ T cells that 
is needed to trigger replication of the non-induced viral clones that are refractory to a 
single round of T cell activation (Ho et al., 2013). 
The CD3/CD28 assay presented here represents a less expensive and less labor 
intensive approach while maintaining the sensitivity similar to that of the conventional 
QVOA. As such, we strongly believe this assay will be valuable in evaluating strategies 
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1. Wash Media 
To Make Stock 
3L 10x PBS pH 7.2-7.4 – Invitrogen 70011044 
 6x 500mL bottles 
600mL New Born Calf Serum – Invitrogen 26010074 
 1x 500mL bottles 
 1x 100mL from 2nd bottle 
300mL 10% w/v dextrose – Fisher 118058 
 30g/300mL 
 Mix 250mL Deionized Water and 30g – stir on plate 
 Use graduated cylinder to adjust volume to 300mL 
300mL Pen-Strep – 15140-122 
 3x 100mL bottle 
360mL Hepes 1M pH 7.2 – 15630-080 
 3x 100mL bottle 
 1x 60mL from 4th bottle 
Using 6L flask 
Add 100 NBCS and 60mL Hepes 
Add remaining ingredients (add remaining NBCS last) 
Aliquot 456mL/500mL autoclaved bottle – do not filter 
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 6x store in -20C 
 2x store in 4C 
 2x dilute to working concentration 
To Make Working Solution 
In 6L flask 
Add 1 stock (456mL) 
Add MilliQ water to 3L 
Filter into 1L bottles using bottle top filter 




100x (Working Solution) 
Order from Sigma-Aldrich, Cat #3149-100ku 
1. Fill 2 50mL conical tubes with 1x PBS (pH 7.2) 
2. Add 10mL from conical to the Heparin container 
3. Mix, remove, put into 100mL beaker 
4. Repeat steps 2 and 3 until all 100mL has been used 
5. Put 50mL solution back into each 50mL conical tube 
6. Steriflip both 
7. Aliquot 1.8mL into 2mL flat bottom cryovials (optional) 
8. Store at 4C  
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3. B-Cell Media (BCM) 
500mL RPMI (Invitrogen 61870036) 
5.5mL Penn/Strep (Invitrogen 15140122) 
55mL Heat Inactivated (HI) FBS (Gemini 100-106) 
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4. Super T-Cell Media (STCM) 
500mL RPMI (Invitrogen 61870036) 
5.5mL Penn/Strep (Invitrogen 15140122) 
55mL Heat Inactivated (HI) FBS (Gemini 100-106) 
T-Cell Growth Factor (~5-10mL) *for further preparation instructions, refer to (Siliciano 
& Siliciano, 2005) 
240 uL IL-2 (Final Concentration 100U/mL) 
-spin down aliquot before using 
 
IL-2 is called Proleukin (Novartis), order from Hopkins Pharmacy 
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5. Phytohaemagglutinin (PHA) 
150 ug/ml 
Manufacturer Remel Inc. 
Order from Fisher, Cat # R30852801 
Work in the hood to make the following: 
PHA comes as 2mg/bottle 
 Add 5 ml wash media to the bottle 
 Transfer to 50 ml conical tube (Be sure to rinse around the lid for powder residue) 
 Add 8.3 ml wash media to the bottle (wash) 
 Transfer to the same 50 ml conical tube (FV = 13.3 ml) 
 Use steriflip to filter 
 Aliquot 0.5 ml into conical 1ml cryovials 
 Store in -80C 






1. Counting Cells Using Hemocytometer 
Materials: 
1. Hemocytometer (any standard with four 16 corner squares is sufficient)  
2. Trypan blue viability dye (Gibco 15250061) 
3. 96-well round bottom plate for mixing cells and viability dye 
Methods 
1. Prepare cell-trypan blue dilution (50 ul : 50 ul = 2-fold dilution; 10 ul : 90 ul = 
10=fold dilution) in a 96-well plate 
2. Place the mixture in the hemocytometer 
3. Calculate the average number of cells from two sets of the 16 corner squares 
4. Multiply by 10,000 (104) 
5. Multiply by the appropriate dilution factor   
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2. Lymphocyte Isolation by Ficoll Gradient 
Materials 
1. Ficoll-Paque Plus (GE Healthcare, 71-7167-00 AG) 
2. Appropriate tubes and pipettes 
3. Wash media (WM) 
Methods 
1. In 50 ml conical tube place 15 ml ficoll 
2. Slowly overlay 30 ml of blood on top of the ficoll layer being careful not to 
disturb the ficoll layer (use slow setting on the pipette) 
3. Spin at 1300 RPM for 35 mins at room temperature with NO BRAKE 
4. During spin, prepare appropriate number of 50 ml conical tubes with wash media 
for the next step 
5. You will then see a gradient with plasma on top, lymphocytes in a white fluffy 
layer, ficoll, then RBCs at the bottom of the tube 
6. Aspirate the top layer (or keep the plasma if experiments asks for it) to about 5 ml 
above the lymphocyte layer 
7. Using a 10 ml pipette carefully remove the white fluffy layer, being careful not to 
take any RBCs 
8. Place lymphocytes in the conical tubes from step 4 
9. Spin at 1400 RPM for 12 mins at 4C 
10. If too many RBC, can ACK treat (consult the experimental directions before 
doing it) 
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11. If more than one tube in the previous step, pool the pellets together in one tube 
with appropriate amount of wash media 
12. Spin at 1400 RPM for 12 mins at 4C 
13. Resuspend in appropriate media and count 
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3. Isolation and Purification of CD4+ T cells 
Materials: 
1. Human CD4+ T Cell Isolation Kit, Miltenyi Biotec. 130-096-533 
2. LS columns (Miltenyi Biotech, 130-042-401) 
3. Magnetic Field, Miletnyi 130-042-303 
4. Wash Media (WM) 
5. Appropriate media for downstream applications, conical tubes and pipettes 
Methods: 
1. After washing PBMCs, perform steps below (per 107 cells) 
2. Add: 
- 40 ul of WM 
- 10 ul CD4 cocktail beads 
3. Mix and incubate for 5 min at 4C 
4. Add: 
- 30 ul of WM 
- 20 ul of anti-biotin microbeads 
5. Mix and incubate for 10 min at 4C 
6. Place appropriate number of LS columns in the magnetic field and put a 50ml 
conical tube under the column 
7. Wash with 3 ml cold wash media 
8. Add the cells (max 150x106 cells per LS column) 
9. Do two more washes of the LS column with cold WM 
10. Count the CD4+ T cells.  
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11. Spin cells at 1200RPM for 10 min at 4C 
12. Resuspend cells in appropriate media for downstream applications 
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4. Isolation and Purification of resting CD4+ T cells 
Materials: 
1. Anti-HLA-DR Microbeads, Miltenyi Biotec 
2. CD25 Microbeads, Miltenyi Biotec 
3. CD69 Microbead Kit II, Miletnyi Biotec 
4. LS columns (Miltenyi Biotech, 130-042-401) 
5. Magnetic Field, Miletnyi 130-042-303 
6. Wash Media (WM) 
7. Appropriate media for downstream applications, conical tubes and pipettes 
Methods: 
1. For depletion of activated CD4+ T cells, perform steps below (per 107 cells) 
2. Add: 
- 40 ul of WM 
- 10 ul of CD69 beads 
3. Mix and incubate for 15 min at 4C 
4. Add: 
- 30 ul of WM 
- 20 ul of anti-CD69 microbeads 
- 10 ul of CD25 beads 
- 10 ul of HLA-DR beads 
5. Mix and incubate for 15 mins 
6. Add 30 ml of cold WM and spin for 10 min at 1200 RPM 
7. Resuspend the resting CD4+ T cells in 500 ul of cold WM  
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8. Place appropriate number of LS columns in the magnetic field and put a 50ml 
conical tube under the column 
9. Wash with 3 ml cold wash media 
10. Add the cells from step 7 (max 150x106 of initial cells from step 1 per LS 
column) 
11. Do two more washed of the LS columns with cold WM 
12. Count the resting CD4+ T cells 
13. Spin cells at 1200 RPM for 10 min at 4C 
14. Resuspend purified resting CD4+ T cells in appropriate media for downstream 
applications  
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5. Preparation of Irradiated PBMC (Feeders) 
Materials 
1. Ficoll-Paque Plus (GE Healthcare, 71-7167-00 AG) 
2. Appropriate tubes and pipettes 
3. Wash media (WM) 
4. PHA 
5. STCM 
6. Bucket with ice 
Methods: 
1. Collect healthy donor blood (120-180 ml depending on the experiment) and 
irradiate the blood to inactivate the cells (10 fold higher number of irradiated 
PBMCs than purified resting CD4+ T cells are needed)  - irradiation 14 min with 
5000R in a Cesium source irradiator 
2. Ficoll separate PBMC from whole blood and wash according to Methods 2. 
3. Resuspend PBMCs in STCM at appropriate concentration 
4. PHA is added to the cell suspension at 1 ug/ml (final concentration in the co-
culture = 0.5 ug/ml 
5. Tube is immediately placed on ice to prevent macrophages from adhering to the 
tub  
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6. Removal of PHA and Addition of Blasts to Culture Assay 
Materials: 
1. Appropriate conical tubes and pipettes 
2. STCM 
Methods: 
1. Carefully remove media without disturbing the cells: 
- 6-well plate: 6 ml removed 
- 24-well plate: 1.5. ml removed 
2. Replace with the same quantity of STCM (fill slowly) 
3. Let cells settle for at least 3 hours. 
4. Isolate CD4+ lymphoblasts from the earlier preparation  
5. Add the appropriate number of CD4+ T cell lymphoblasts 
- 6-well plate: 4x106 cells are added in 6 ml STCM. This amount is optimal, can 
do with half the amount (in the same volume of STCM) with limited numbers 
- 24-well plate: 1x106 cells are added in 1.5 ml STCM. This amount is optimal, 




7. Production of CD4+ Lymphoblasts (Blasts) 
Materials: 
1. Ficoll-Paque Plus (GE Healthcare, 71-7167-00 AG) 
2. Appropriate tubes and pipettes 




1. Ficoll healthy donor PBMC from whole blood (60-180 ml) 
2. After the pellet has been washed adequate times, resuspend it in 30 ml STCM 
3. Add 100 ul PHA 
4. Transfer cells to a 75 ml flask 
5. Incubate upright for 2-3 days at 37C under 5% CO2  
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8. Isolation and Purification of CD4+ T cells lymphoblasts 
Materials 
1. Human CD4+ T Cell Isolation Kit, Miltenyi Biotec. 130-096-533 
2. LS columns (Miltenyi Biotech, 130-042-401) 
3. Magnetic Field, Miletnyi 130-042-303 
4. Appropriate tubes and pipettes 
5. Wash media (WM) 
6. STCM 
Methods: 
1. Add the PBMC in PHA from earlier step (30 ml) into a 50 ml conical tube and 
wash the flask with 10 ml cold WM 
2. Count cells 
3. Centrifuge cell suspension at 1400 RPM for 12 min at 4C 
4. After washing PMBC, isolate CD4+ T cells as described in Method 3 
7. Add appropriate amount of STCM for the final concentrations as determined by 
the amount of wells plated  
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9. p24 ELISA 
Materials: 
1. P24 ELISA kit 
2. 24-well plate = 3.4 ml/well (48-well plate = 1.6ml/well) 
3. Wash media (WM) 
Things to do before starting: 
1. Reagent preparation 
a. Equilibrate all reagents to room temp (15-30C) before use 
2. Plate wash concentrate (WC) 
a. Make 1X from stock = 1 part WC + 19 H2O 
i. ~1000ml of WC is used per plate assayed  
Methods: 
1. Prepare standard 
a. Label wells of a 24-well plate A-G 
b. Add 980 ul WM to A 
c. Add 975 ul WM to B 
d. Add 500ul WM to C-G 
e. Add 20ul p24 standard to A 
f. Mix with p1000 by pipetting up and down to the max 
g. Transfer 25ul of A to B 
h. Mix with p1000 by pipetting up and down to the max 
i. Serial dilute from B-F with 500ul 
2. Prepare sample in a 96-well plate 
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a. Perform dilutions if necessary (concentrated virus normally 1:10^5 – 
1:10^8 range work, use a necessary volume and corresponding amounts of 
the virus) 
i. 1:10^2 => 297ul WM + 3ul Virus stock = A 
ii. 1:10^3 => 270ul WM + 30 ul A = B 
iii. 1:10^4 => 270ul WM + 30 ul B = C 
iv. 1:10^5 => 270ul WM + 30 ul C = D 
v. 1:10^6 => 270ul WM + 30 ul D = E 
vi. 1:10^7 => 270ul WM + 30 ul E = F 
vii. 1:10^8 => 270ul WM + 30 ul F = G 
3. Collect necessary strips of mAb-coated wells (need a standard for each plate) 
4. Add 20ul Triton to each well 
5. Add 180ul of sample (including standard) to each well 
6. Incubate at 37C for 1-2 hrs (can do overnight if necessary – in this case store in 
the fridge at 4C) 
7. Wash – plate washer ideal (using p24 wash) – blot well 
8. Add 100ul detector Ab to each well 
9. Incubate at 37C for >45 mins 
10. Wash – blot well 
11. Add 100ul streptavidin mixture 
a. 10ul concentrate + 1ml diluent 
b. Make 1 ml per strip – adjust accordingly 
12. Incubate at room temp > 25mins 
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13. Wash – blot well 
14. Add 100ul substrate 
a. 11ml diluent + 1 tablet 
b. Make 2 if necessary 
c. PROTECT FROM LIGHT 
15. Incubate at room temp for > 25mins 
a. PROTECT FROM LIGHT 
16. Add 100ul stop solution 
a. Read within 15 mins of stopping the reaction 
17. Read plate  






1. FACT tubes (5 ml) 
2. DynaMag – 5 Magnet (ThermoFisher Scientific, 12303D) 
3. PBS 
4. Appropriate antibodies 
5. Cytofix/Cytoperm (BD, 554714) 
Methods: 
Removal of the microbeads: 
1. For each sample, first remove the dynabeads: 
2. Transfer each well into its own 5 mL FACS tube. 
3. Spin down for 5 minutes at 1400 rpm at 4°C. 
4. Remove all but 200 uL of media and then resuspend the pellet. 
5. Place the FACS tube in the magnetic tube rack and wait for one minute to allow 
for the magnetic beads to attach to the side 
6. Transfer the cell suspension (sans dynabeads) to another 5 mL FACS tube. 
7. Repeat for each sample. 
Staining Procedure (for microbead-treated cells, in our case <1x106 cells total) 
1. Spin down tubes at 1400 rpm for 3 minutes at 4°C. 
2. Wash with PBS and spin down again. 
3. In the meantime, make up the master stain in PBS: 
a. 50 µL of PBS for each well. 
b. 1 µL of each stain per well (ex. if three antibodies, add 1 µL of each stain). 
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c. For this activation panel, add: 
i. CD3-PacBlue, CD8-APC•H7, CD4-PE 
ii. HLA-A2-PerCP•Cy5.5 
iii. CD25-FITC, HLA-DR-APC, CD69-BV605 
4. Remove supernatant from tubes and add 50 µL master stain to each well. 
5. Incubate for 25 minutes at 4°C on ice. 
6. Add 1mL of PBS to each tube and spin down. 
7. Remove supernatant and wash an additional two times with 1mL each. 
8. Resuspend in 100 µL PBS and run on the FACS Canto. 
a. Can fix cells (resuspend in 200 ul of fixative – Cytofix/Cytoperm) at this 
point and run FACS later (need to wash off before running the samples) 
For PHA and feeders stimulated wells (in our case >1x106 cells) 
1. Spin down cells in a FACS tube 
2. 2. Make up master stain in PBS 
a. 50 µL of PBS for each well. 
b. 5 µL of each stain per well (ex. if three antibodies, add 5 µL of each stain). 
c. For this activation panel, add: 
i. CD3-PacBlue, CD8-APC•H7, CD4-PE 
ii. HLA-A2-PerCP•Cy5.5 
iii. CD25-FITC, HLA-DR-APC, CD69-BV605  
3. Remove supernatant from tubes and add 80 µL master stain to each well. 
4. Incubate for 25 minutes on ice. 
5. Add 1mL of PBS to each well and spin down. 
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6. Remove supernatant and wash an additional two times with 1mL each. 
7. Resuspend in 100 µL PBS and run on the FACS Canto. 
a. Can fix cells (resuspend in 200 ul of fixative – Cytofix/Cytoperm) at this 





1. Check fluid levels 
2. Turn on the machine 
3. Perform fluidics startup with HTS attached 
4. Set up experiment 
i. Keywords 
ii. Color labels 
5. Run sample 
i. Flow rate should be < 10,000 events per second 
ii. If cells have been sitting, resuspend 
iii. When selecting volume for HTS, always leave 25% of sample 
6. If last user for the day, perform fluidics shutdown with HTS attached 
7. After shutdown complete, turn off machine 
8. Export FCS files 
9. Analyze data on FlowJo  
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Johns Hopkins Bloomberg School of Public Health, 
Department of Molecular Microbiology and Immunology 
Johns Hopkins University School of Medicine, Division of 
Infectious Diseases, Department of Medicine 
Masters Student in the laboratory of Dr. Joel N. Blankson 
Baltimore, MD 
Nov. 2014 – May 2016 
 Development of an improved version of the conventional Quantitative Viral 
Outgrowth Assay (QVOA) by means of alternative activation of CD4+ T cells and 
consequent elimination of the feeder cells 
 Cloning and sequence characterization of HIV NL4-3 constructs with Gag 
sequences derived from HIV-infected individuals with undetectable viral loads 
currently on or without therapy 
 Analysis of the CTL response to Gag clones derived from HLA-B-57+ HIV-
infected individuals using suppression assays followed by appropriate flow 
cytometric analysis 
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Harvard Medical School, New England Primate Research 
Center, Division of Immunology 
Research Assistant in the laboratory of Dr. R. Paul Johnson 
Southborough, MA 
Sept. 2009 – Jan. 2012 
 Identification and characterization of novel molecular interactions in HIV models 
in primates with focus on NKG2D receptor and its corresponding ligands 
 Organization and implementation of novel protocols for the optimization of custom 
TaqMan probes for use in real-time PCR assays on various platforms (Applied 
Biosystems, Fluidigm) 
 Refinement of the analysis of high-throughput real-time PCR raw data (Fluidigm) 
with custom written VBA 
 Development of novel bioinformatics protocols with incorporation of Geneious 
software with implementation of cross-sharing capabilities for sequence analysis 
using a localized SQL server (Streamlined protocols for the development of custom 
TaqMan probes for use in real-time PCR assays 
Harvard Medical School, New England Primate Research 
Center, Division of Immunology 
Summer Research Internship in the laboratory of Dr. R. Paul 
Johnson 
Southborough, MA 
May – Aug. 2008 
 Performed ficoll gradient isolation of lymphocytes from the whole blood following 
standard protocols 
 Assisted in lymphocyte collection and enrichment for NK cells by negative 
selection magnetic bead separation 
 Identified potential regions for sequence-specific primers (SSPs) for killer 
immunoglobulin-like receptors (KIRs) by performing multiple mRNA sequence 
analysis  
Vanderbilt University, Department of Chemistry 
Summer Research Internship in the laboratory of Dr. Michael 
P. Stone 
Nashville, TN 
May – Aug. 2007 
 Obtained 1-D and 2-D NMR spectra of double-stranded B-DNA duplex on Bruker 
Spectrometers 
 Analysed and assigned corresponding NMR peaks (NOESY, COSY) for 
downstream structural analysis 
 Refined the final structure of the duplex oligonucleotide, generated in Insight II, by 
measuring NOESY Cross Peak Volumes 
 Calculated interproton distances by Relaxation Matrix Analysis (MARDIGRAS) 
 Derived a semi-final 3D structure of the duplex using Restrained Molecular 
Dynamics in the AMBER force field 
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Moscow Research Institute MONIKI, Department of 
Thoracic Surgery 
Summer Research Internship in under Dr. Vladimir 
Aleksandrovich 
Moscow, Russia 
May – Aug. 2006 
 Maintained patient history and improved the efficiency of database entries by 
rewriting the SQL code 
 Conducted statistical analysis on the outcomes of treatment of patients suffering 
from complex regional pain syndrome 
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Johnson.  The Journal of Immunology, May 2012, 188, 113.18 
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Induce Cytotoxicity in ROR gamma t+NKp44+ Mucosal NK Cells During SIV 
Infection.” R. Reeves, P. Rajakumar, T. I. Evans, M. Connole, J. Gillis, Y. 
Kuzmichev, R. Johnson. Conference Paper in AIDS Research and Human 
Retroviruses. Oct. 2011  
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4.“Differential Expression of Transcription Factors in SIV-Specific CD8+ T cells at 
Week 5 and Week 20 After Vaccination with SIV239 Delta nef.” J. M. Billingsley, 
P. A. Rajakumar, N. C. Salisch, Y. V. Kuzmichev, M. A. Connole, R. K. Reeves, R. 
P. Johnson. Conference Paper in AIDS Research and Human Retroviruses.  
Sep. 2011 
5.“Evaluation of coumarin derivatives as anti-fungal agents against soil-borne fungal 
pathogens.” Brooker NL, Kuzmichev Y, Laas J, Pavlis R. Communications in 




1. “Quantification of HIV-1 Latent Reservoir Using Physiological Activation of 
CD4+ T Cells.” Yury V. Kuzmichev, Christopher W. Pohlmeyer, Victoria E. K. 
Walker-Sperling, and Joel N. Blankson. Poster session at the 32nd Clinical Virology 
Symposium, meeting of the American Society of Microbiology, Daytona Beach, 
FL, May 19-22, 2016. Poster session at the 2016 Department of Medicine Research 
Retreat, Johns Hopkins University School of Medicine, Baltimore, MD, Mar. 8, 
2016 
2. “Differential Expression of Transcription Factors in SIV-specific CD8+ T Cells at 
Week 5 and Week 20 After Vaccination with SIV239nef.” James M. Billingsley, 
Premeela A. Rajakumar, Yury V. Kuzmichev, Nadine C. Salisch, Michelle 
Connole, R. Keith Reeves, and R. Paul Johnson. Poster session at the AIDS 
Vaccine 2011, Bangkok, Thailand, Sep. 12-15, 2011. 
3.“Molecular Cloning and Characterization of NKG2D Ligands in Rhesus 
Macaques.” Yury V. Kuzmichev, Henoch S. Hong, Rhona L. Glickman, Premeela 
A. Rajakumar, Gang Qiu, and R. Paul Johnson.  Poster session at the 28th Annual 
Symposium on Nonhuman Primate Models for AIDS, New Orleans, LA,  
Oct. 19-22, 2010. 
4.“Development of Real-Time PCR Assays for the Quantitation of Macaque Killer 
Immunoglobulin-like Receptors (KIR) Sequences.” Emily B. Krulewitz, Yury V. 
Kuzmichev, Arnaud Colantonio, David Evans, Premeela A. Rajakumar, and R. 
Paul Johnson. Poster session at the 12th Annual Poster Session, New England 
Primate Research Center, Harvard Medical School, Southborough, MA, Aug. 11, 
2010. 
5.“Rational Design of Sequence-Specific Primers for Quantification of Natural Killer 
Cell Receptors in Rhesus Macaques.” Yury V. Kuzmichev, R. Keith Reeves, and 
R. Paul Johnson.  Oral Presentation given at the Undergraduate Research 
Colloquium.  Pittsburg State University, Pittsburg, KS, Apt. 29, 2009.  Poster 
session at the Fall 2008 Arkansas INBRE Research Conference, Fayetteville, AR, 
Nov. 7-8, 2008.  Poster session at the 10th Annual Poster Session, New England 
Primate Research Center, Harvard Medical School, Southborough, MA, Aug. 5, 
2008. 
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6.“ACS MoKanOk Local Section.  Student Affiliates 2007-2008.” Yury V. 
Kuzmichev, Anthony Truong, Carrie Nelson, Lindsay Nance, Blake Allen, and 
Khamis Siam.  Poster session at the 10th Annual ChemLuminary Awards poster 
presentation at 236th American Chemical Society National Meeting & Exposition, 
Philadelphia, PA, Aug. 18-20, 2008. 
7.“Resonance Assignment of Double-Stranded DNA using High-Field NMR 
Spectroscopy and its Applications in Determination of its Three-Dimensional 
Structure.”  Yury V. Kuzmichev, Kyle L. Brown, and Michael P. Stone.  Poster 
session at the Fall 2007 Arkansas INBRE Research Conference, Fayetteville, AR, 
Nov. 9-10, 2007.  Poster session the at the 42nd Midwest Regional Meeting of the 
American Chemical Society, Kansas City, MO, Nov. 7-8, 2007. 
8.“Coumarin Derivatives as Novel Antifungal Seed Treatments.” Yury V. 
Kuzmichev, Nancy L. Brooker, Jacob C. Laas, and Robert R. Pavlis.  Poster 
session presented at the 233rd American Chemical Society National Meeting & 
Exposition, Chicago, IL, Mar. 25-29, 2007. 
9. “Thoracic Sympathectomy in Treatment of Complex Regional Pain Syndrome of 
Upper Limbs.”  Golubev V. Kuzmichev. Y., G., Krupatkin A. I., Zeinalov V. T., 
Merkulov M. V., Kuzmichev V.  Poster session at the 7th International Symposium 
on Sympathetic Surgery, Porto de Galinhas, Pernambuco, Brazil, Mar. 20-22, 2007 
10. “Synthesis of Coumarin Derivatives for Possible Use as Soybean Seed 
Treatment.”  Jacob C. Laas, Robert R. Pavlis, Nancy L. Brooker, and Yury V. 
Kuzmichev.  Poster session at the Fall 2006 Arkansas INBRE Research 
Conference, Fayetteville, AR, Nov. 3-4, 2006.  Poster session at the 41st Midwest 
Regional Meeting of the American Chemical Society, Quincy, IL, Oct. 25-27, 
2006. 
UNDERGRADUATE RESEARCH EXPERIENCE 
Pittsburg State University, Department of Chemistry 
Research Assistant in the laboratories of Dr. James McAfee and 
Dr. Irene Zegar 
Jan. – July 2009,  
Jan. – May 2008 
 Used fluorescence technique to investigate the binding of flavonoids to DNA  
 Evaluated binding parameters including binding constants as well as determined 
cooperativity method in various flavonoid compounds 
 Assisted with investigation of the proteins associated with the repressor complex 
Pittsburg State University, Department of Biology 
Research Assistant in the laboratory of Dr. David Gordon 
Jan. – July 2009 
 Modeled human population migration rates in the presence of variable factors 
 Developed custom VBA codes for simplification of the calculations 
82 
Pittsburg State University, Department of Biology 
Research Assistant in the laboratory of Dr. Nancy Brooker 
Sept. 2006 – Apr. 2007 
 Worked on the development of biopesticides for soybean seedling protection 
against early season fungal disease 
 Designed and performed a variety of phytotoxicity experiments in order to better 
understand and describe the toxic effect of compounds on fungal growth 
Pittsburg State University, Departments of Chemistry 
and Physics 
Research Assistant in the laboratories of Dr. Khamis Siam 
and Dr. Robert Backes   
Feb. 2005 – Feb. 2006 
 Maintained and optimized a Beowulf Cluster (12 nodes) using Ubuntu and Open 
MPI 
 Developed and refined Monte Carlo simulation describing the interaction of 
photons as they move through tissue (retina) 
 Assisted with optimization of computational models of the spectral reflectance of 
human eye  
TEACHING EXPERIENCE 
Teaching Assistant 
Graduate Immunology: The Immune Response – 
260.717  
Johns Hopkins Bloomberg School of Public Health 
Mar. – May 2016 
Biochemistry I Laboratory – CHEM*575*01 
Pittsburg State University  
Aug. – Dec. 2007 
Tutor 
English and Russian Language  
Moscow Language Exchange 
May – Aug. 2012, -13 
General Chemistry I and II, Organic Chemistry I and 
II 
Pittsburg State University 
Jan. 2005 – May 2009 
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HONORS, AWARDS, AND FELLOWSHIPS 
Pan American Society for Clinical Virology Travel Award 
American Society for Microbiology 
2016 
Master’s Tuition Scholarship 
Johns Hopkins Bloomberg School of Public Health 
2015 – 2016  
Outstanding Senior 
Pittsburg State University 
2009 
Analytical Chemistry Award 
Pittsburg State University 
2009 
Undergraduate Research Colloquium – 1st Place 
Pittsburg State University 
2009 
International Certificate of Recognition 
Pittsburg State University 
2009 
International Advocate Scholarship 
Pittsburg State University 
2005 – 2008 
Undergraduate Russian Chemistry Scholarship 
Pittsburg State University 
2004 – 2008 
Certificate of Appreciation from the Dean of College of Arts 
& Sciences Student Advisory Committee 
Pittsburg State University 
2009 
Summer Pre-Baccalaureate Training Program Fellowship 
 Harvard Medical School, New England Primate Research Center, 
Division of Immunology 
2008 
ACS ChemLuminary Award National Finalist 
American Chemical Society 236th National Meeting and 
Exposition 
2008 
Undergraduate Research Conference Ark-INBRE – 1st Place 




Golden Gorilla Award 
Pittsburg State University 
2008 
Biochemistry Award 
Pittsburg State University 
2008 
Chemistry Club Chemistry Award 
Pittsburg State University 
2008 
Schoene, Norberta Wachter Scholarship 
Pittsburg State University 
2008 
Summer Research Experience for Undergraduate Fellowship 
Vanderbilt University, Department of Chemistry 
2007 
Undergraduate Research Conference Ark-INBRE – 2nd Place 
Arkansas INBRE Research Conference 
2007 
Certificate of Appreciation Chemistry Club 
Pittsburg State University 
2007 
Undergraduate Research Conference Ark-INBRE – 3rd Place 
Arkansas INBRE Research Conference 
2006 
Gier, Leland J. And Margaret E. Biology Scholarship, Keller, 
Leland Endowment 
Pittsburg State University 
2006 
CRC Freshman Chemistry Achievement Award 
Pittsburg State University 
2005 
EXTRACURRICULAR AND LEADERSHIP EXPERIENCE 
Student Outreach Resource Center (SOURCE), Johns 
Hopkins Bloomberg School of Public Health 
2015-16 Cohort HIV Counseling and Testing Site Leader for 
Sisters Together and Reaching (STAR) 
Oct. – May 2015 
 Managed 9 students by assigning them to respective time slots, facilitated 
communication between respective teams, and increased overall efficiency of the 
site 
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Generation Tomorrow, Johns Hopkins University – 
Center for AIDS Research 
HIV/HCV Counseling and Testing 
Oct. 2014 – Jun. 2016 
 Conducted rapid HIV/HCV testing and counseling on more than 100 patients in 
various locations in Baltimore 
 Assisted in the development of a HIV/HCV risk-reduction campaign for men of 
color focused on sexual behaviour 
Student Assembly, Johns Hopkins Bloomberg School of 
Public Health 
Member-at-Large 
Jun. 2015 – May 2016 
 Presided on the Social Activities Committee (co-organized Fall Formal for 450 
students), Community Affairs Committee (co-organized an STD awareness event), 
and University-wide Health Services Committee (oversight of the health agenda 
for the East Baltimore Campus) 
MMI Student Group, Johns Hopkins Bloomberg School of 
Public Health 
Social Coordinator 
Sept. 2014 – May 2016 
 In charge of planning and organization of game nights for the MMI (Molecular 
Microbiology and Immunology) Student group  
International Injury Research Unit, Johns Hopkins 
Bloomberg School of Public Health 
Russian Translator 
Oct. 2014 
 Assisted in communication between representatives from Russia and other 
countries during annual meeting 
Chemistry Club (ACS Student Affiliate Chapter)  
Pittsburg State University 
President 
Sept. 2006 – May 2009 
 Led the club to be nominated for a National American Chemical Society (ACS) 
Award ChemLuminary 2008 MOKANOK (Missouri, Kansas, Oklahoma) local 
section for outstanding celebration of Earth Day 
 Responsible for leading a team of 20 during National Chemistry Week 2008 where 
the club was responsible for organization of Chemistry Magic Shows for 
Elementary and Middle Schools in the surrounding areas (4 TV appearances in 7 
days) 
 Coordinated the establishment of annual Chemistry Club Scholarship to high 
school seniors interested in chemistry 
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 Expanded the club membership from five to 50 active members 
 Organization of various fund-raisers, Garage Sale, a highway cleanup, 
ChemPardy, adopt a family for Thanksgiving and Christmas, celebration of Mole 
Day, Earth Day, Science Day, and the Chemistry Olympiad 
Admissions Office, Pittsburg State University 
Student Ambassador 
Aug. 2008 – Feb. 2009 
 Responsibilities included serving one hour a week in the Admissions Office, 
visiting with prospective students, taking visitors to campus appointments, giving 
campus tours, and assisting with various on-campus events, such as “Jungle Day” 
Student Advisory Council, College of Arts and Sciences, 
Pittsburg State University 
Departmental Representative 
Sept. 2008 – May 2009 
 Promoted interests of the Chemistry Department (e.g. increase in the number of 
tutors for midterm and final examinations) 
 Acted as a liaison between the Department of Chemistry and the Dean of College 
of Arts and Sciences 
Student Government Association, 
Pittsburg State University 
Senator 
Jan. – May 2008 
 Promoted the Student Government Association and its projects and initiatives at 
Pittsburg State University 
 Assisted on various projects with the Student Body Board of Elections and 
Academic Affairs Committee (e.g. nomination and selection of outstanding 
faculty) 
Crimson Club, Pittsburg State University 
Member 
Aug. 2006 – May 2007 
 Represented the student body and the Office of the President at such events as the 
President’s Society Dinner, receptions for international visitors, major donors, 
distinguished faculty, and assisted during campus tours by state and federal 
government officials 
International Student Association 
Pittsburg State University 
International Advocate 
Aug. 2005 – May 2009 
 Assisted during orientations for new international students, organized cultural 
presentations and food exchanges 
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Pre-Med Club, Pittsburg State University 
Member 
Sept. 2004 – May 2009 
 Contributed to the “Pre-Med Buddy System” by advising students on class 
schedules, shadowing opportunities, and research tracks, participated in various 
fundraisers 
Biology Club, Pittsburg State University 
Member 
Sept. 2004 – May 2009 
 Designed a beta version of the club website 
OTHER EMPLOYMENT 
MEDEX LLC 
Project Manager and Marketing Assistant 
Moscow, Russia 
Mar. 2012 – Aug. 2014 
 In charge of coordination of educational seminars for physicians on major 
products from the company’s portfolio including SWI-STO II Iontophorese and 
implants for treating erectile dysfunction and urinary incontinence (AMS 800, 
AMS 700MS) 
 
 Coordinated development and deployment of a web application for doctor-patient 
interactions and appointment scheduling 
 
 Revised and updates advertising campaigns for company’s products (Human 
Energy 107, Maxim, Odoban, DRY24, and surgical equipment) 
 
VOLUNTEERING AND OTHER ACTIVITIES 
VOLUNTEERING 
Moscow Research Institute MONIKI 
Preventive Medicine 
Moscow, Russia 
Aug. 2012 – Aug. 2013 
 Assisted in organization of health screening booths offering cholesterol, blood 
glucose level, and blood pressure testing for over 2000 patients 
 Coordinated efforts to encourage patients to keep a list of their current medications 
within a medicine bottle for easy access in case of an emergency through 
promoting the Vial of Life (adapted for use in Russia) 
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Marlborough Hospital 
Assistant in the Transportation Department 
Marlborough, MA 
Oct. 2011 – Mar. 2012 
 Transported patients from their rooms to various treatment areas and back 
 Delivered supplies and materials from central supply to assigned areas 
Meals on Wheels, Mt. Carmel Regional Medical 
Center Dietary Department 
Driver/Deliverer 
Pittsburg, KS 
Jan. – May 2009 
 Delivered an average of 150 meals during each month to elderly and disabled 
persons 
Moscow Research Institute MONIKI 
Critical Care Medicine 
Moscow, Russia 
May – Aug. 2004 
 Comforted patients and their family members in waiting rooms 
 Directed incoming patients to appropriate areas (triage, registration, recreation 
area) 
 Performed suture removal and participated in the change of medical dressings 
MEDICAL SHADOWING EXPERIENCE 
Moscow Research Institute MONIKI Moscow, Russia 
 Department of Critical Care Medicine May – Aug. 2013 
 Department of Thoracic Surgery May – Aug. 2006 
Carolinas Medical Center and Heineman Medical 
Research Center 
Charlotte, NC 
 Department of Thoracic and Cardiovascular Surgery May 2010 
SLUCare, Des Peres Medical Arts Pavilion  St. Louis, MO 
 Division of Cosmetic and Laser Surgery Aug. 2007 
Newton Memorial Hospital and Neurologic Arts 
Associated LLC 
Newton, NJ 
 Department of Neurology Dec. 2005 – Jan. 2006 
Faith Regional Health Services Norfolk, NE 
 Department of Cardiovascular and Thoracic Surgery Dec. 2004 – Jan. 2005 
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PROFESSIONAL MEMBERSHIPS AND HONOR SOCIETIES  
 American Society for Microbiology. American Chemical Society, Omicron Delta 
Kappa, Phi Kappa Phi, TriBeta Biological Honor Society 
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